In addition, in other epithelial cell carcinomas, such as gastric carcinoma, breast cancer and melanoma, patients in the CTNND1-high group also showed poor immunotherapeutic response than those in the CTNND1-low group (Supplementary Figure 5A-5C). This evidence concerns the gene CTNND1 and breast cancer.